IQVIA Holdings Inc. $IQV Shares Bought by GDS Wealth Management

GDS Wealth Management increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 31.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,491 shares of the medical research company’s stock after purchasing an additional 21,020 shares during the period. GDS Wealth Management owned 0.05% of IQVIA worth $13,788,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Everpar Advisors LLC grew its holdings in IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after buying an additional 62 shares during the period. Private Trust Co. NA increased its position in IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after purchasing an additional 67 shares during the last quarter. Independent Advisor Alliance raised its stake in IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after purchasing an additional 72 shares during the period. Nemes Rush Group LLC boosted its holdings in shares of IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 81 shares during the last quarter. Finally, Penserra Capital Management LLC grew its stake in shares of IQVIA by 10.3% during the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after buying an additional 90 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on IQV shares. JPMorgan Chase & Co. lifted their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Evercore ISI lifted their price objective on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. Truist Financial reissued a “buy” rating and set a $265.00 target price (up previously from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Mizuho increased their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $240.61.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Up 0.1%

NYSE IQV opened at $217.50 on Thursday. The stock has a market cap of $37.04 billion, a P/E ratio of 29.84, a PEG ratio of 2.44 and a beta of 1.34. The company’s fifty day simple moving average is $204.51 and its 200-day simple moving average is $180.05. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $228.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.